What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “DMR-001 will be administered at protocol defined dose at a frequency of every 4 weeks.”In the company’s words, NCT07849231 on ClinicalTrials.gov
- Tested for
- Myeloproliferative Neoplasms (MPNs)
- Main trialPhase 1
- “This is a multi-center, open-label, Phase 1/1b study designed to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary efficacy of DMR-001 monotherapy in adult participants with CALR-mutated essential thrombocythemia (ET) and myelofibrosis (MF), and of DMR-001 in combination with ruxolitinib in participants with CALR-mutant MF.”In the company’s words, NCT07849231 on ClinicalTrials.gov
Other drugs for Myeloproliferative Neoplasms (MPNs)
- GivinostatItalfarmaco · Phase 3
- NavitoclaxAbbVie · Phase 3
- NavtemadlinKartos Therapeutics, Inc. · Phase 3
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Radotinib HClIl-Yang Pharm. Co., Ltd. · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
Coming up1
- Jun 2030Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | Jun 2030 | A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026